Inhibition of Cyclin-dependent Kinase (CDK) Decreased Survival of NB4 Leukemic Cells: Proposing a P53-Independent Sensitivity of Leukemic Cells to Multi-CDKs Inhibitor AT7519

Overview

Journal Iran J Pharm Res

Publisher Brieflands

Specialty Pharmacology

Date 2021 Mar 8

PMID 33680018

Citations 2

Authors

Atieh Pourbagheri-Sigaroodi

Ava Safaroghli-Azar

Mehrnoosh Shanaki

Amir-Mohammad Yousefi

Ali Anjam Najmedini

Davood Bashash

Affiliations

Soon will be listed here.

Abstract

An unbounded number of events exist beneath the intricacy of each particular hematologic malignancy, prompting the tumor cells into an unrestrained proliferation and invasion. Aberrant expression of cyclin-dependent kinases (CDKs) is one of these events which disrupts the regulation of cell cycle and subsequently, results in cancer progression. In this study, we surveyed the repressive impact of multi-CDK inhibitor AT7519 on a panel of leukemia-derived cell lines. Our data underlined that AT7519 abated the survival of all tested cells; however, in an overview, the response rate of leukemic cells to the inhibitor was varied irrespective of p53 status. Notably, the less sensitivity of leukemia cells to AT7519 was found to be mediated partly by the compensatory activation of c-Myc oncogene which was confirmed by the induction of a superior cytotoxicity upon its suppression in less sensitive cell. The blockage of cell cycle, as announced by induction of sub-G1 arrest as well as reduced S phase, resulted in a significant decrease in survival of acute promyelocytic leukemia (APL)-derived NB4 cells, as the most sensitive cell line, either as monotherapy or in combination with arsenic trioxide. Anti-leukemic effects of the inhibitor were further verified by apoptosis analysis, where we discovered that AT7519 induced apoptosis via alteration of pro- and anti-apoptotic genes in NB4. All in all, this study proposed that AT7519 is a rewarding agent opposed to APL; however, additional examinations should be performed to determine the advantages of this inhibitor in clinical setting.

Citing Articles

The CDK inhibitor AT7519 inhibits human glioblastoma cell growth by inducing apoptosis, pyroptosis and cell cycle arrest.

Zhao W, Zhang L, Zhang Y, Jiang Z, Lu H, Xie Y Cell Death Dis. 2023; 14(1):11.

PMID: 36624090 PMC: 9829897. DOI: 10.1038/s41419-022-05528-8.

Cdk2 suppresses IL-23 expression and the onset of severe acute pancreatitis.

Ma Y, Liu L, Li B, Wang W, Zhao T Immun Inflamm Dis. 2022; 10(6):e631.

PMID: 35634959 PMC: 9119007. DOI: 10.1002/iid3.631.

References

Wade M, Wahl G . c-Myc, genome instability, and tumorigenesis: the devil is in the details. Curr Top Microbiol Immunol. 2006; 302:169-203. DOI: 10.1007/3-540-32952-8_7. View

Asghar U, Witkiewicz A, Turner N, Knudsen E . The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015; 14(2):130-46. PMC: 4480421. DOI: 10.1038/nrd4504. View

Sheikh-Zeineddini N, Bashash D, Safaroghli-Azar A, Riyahi N, Shabestari R, Janzamin E . Suppression of c-Myc using 10058-F4 exerts caspase-3-dependent apoptosis and intensifies the antileukemic effect of vincristine in pre-B acute lymphoblastic leukemia cells. J Cell Biochem. 2019; 120(8):14004-14016. DOI: 10.1002/jcb.28675. View

Filippi-Chiela E, Villodre E, Zamin L, Lenz G . Autophagy interplay with apoptosis and cell cycle regulation in the growth inhibiting effect of resveratrol in glioma cells. PLoS One. 2011; 6(6):e20849. PMC: 3113895. DOI: 10.1371/journal.pone.0020849. View

Bendris N, Lemmers B, Blanchard J . Cell cycle, cytoskeleton dynamics and beyond: the many functions of cyclins and CDK inhibitors. Cell Cycle. 2015; 14(12):1786-98. PMC: 4614797. DOI: 10.1080/15384101.2014.998085. View

Sanchez-Martinez C, Lallena M, Sanfeliciano S, de Dios A . Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019). Bioorg Med Chem Lett. 2019; 29(20):126637. DOI: 10.1016/j.bmcl.2019.126637. View

Wyatt P, Woodhead A, Berdini V, Boulstridge J, Carr M, Cross D . Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J Med Chem. 2008; 51(16):4986-99. DOI: 10.1021/jm800382h. View

Riyahi N, Safaroghli-Azar A, Sheikh-Zeineddini N, Sayyadi M, Bashash D . Synergistic Effects of PI3K and c-Myc Co-targeting in Acute Leukemia: Shedding New Light on Resistance to Selective PI3K-δ Inhibitor CAL-101. Cancer Invest. 2019; 37(7):311-324. DOI: 10.1080/07357907.2019.1651328. View

Gao S, Liu F . Novel insights into cell cycle regulation of cell fate determination. J Zhejiang Univ Sci B. 2019; 20(6):467-475. PMC: 6568219. DOI: 10.1631/jzus.B1900197. View

10.

Cihalova D, Staud F, Ceckova M . Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro. Cancer Chemother Pharmacol. 2015; 76(1):105-16. DOI: 10.1007/s00280-015-2772-1. View

11.

Bashash D, Ghaffari S, Zaker F, Kazerani M, Hezave K, Hassani S . BIBR 1532 increases arsenic trioxide-mediated apoptosis in acute promyelocytic leukemia cells: therapeutic potential for APL. Anticancer Agents Med Chem. 2013; 13(7):1115-25. DOI: 10.2174/18715206113139990126. View

12.

Fujiwara K, Daido S, Yamamoto A, Kobayashi R, Yokoyama T, Aoki H . Pivotal role of the cyclin-dependent kinase inhibitor p21WAF1/CIP1 in apoptosis and autophagy. J Biol Chem. 2007; 283(1):388-397. DOI: 10.1074/jbc.M611043200. View

13.

Kang M, Kim W, Jo H, Shin Y, Kim M, Jeong J . Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS‑032, on cervical cancer. Int J Oncol. 2018; 53(2):703-712. DOI: 10.3892/ijo.2018.4424. View

14.

Malumbres M, Pevarello P, Barbacid M, Bischoff J . CDK inhibitors in cancer therapy: what is next?. Trends Pharmacol Sci. 2007; 29(1):16-21. DOI: 10.1016/j.tips.2007.10.012. View

15.

Xi C, Wang L, Yu J, Ye H, Cao L, Gong Z . Inhibition of cyclin-dependent kinases by AT7519 is effective to overcome chemoresistance in colon and cervical cancer. Biochem Biophys Res Commun. 2019; 513(3):589-593. DOI: 10.1016/j.bbrc.2019.04.014. View

16.

Lee J, Moon M, Min H, Chung H, Park E, Park H . Induction of apoptosis by a novel indirubin-5-nitro-3'-monoxime, a CDK inhibitor, in human lung cancer cells. Bioorg Med Chem Lett. 2005; 15(17):3948-52. DOI: 10.1016/j.bmcl.2005.05.105. View

17.

Squires M, Cooke L, Lock V, Qi W, Lewis E, Thompson N . AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol Cancer Ther. 2010; 9(4):920-8. DOI: 10.1158/1535-7163.MCT-09-1071. View

18.

Bayati S, Bashash D, Ahmadian S, Safaroghli-Azar A, Alimoghaddam K, Ghavamzadeh A . Inhibition of tachykinin NK receptor using aprepitant induces apoptotic cell death and G1 arrest through Akt/p53 axis in pre-B acute lymphoblastic leukemia cells. Eur J Pharmacol. 2016; 791:274-283. DOI: 10.1016/j.ejphar.2016.09.006. View

19.

Tasdemir E, Maiuri M, Tajeddine N, Vitale I, Criollo A, Vicencio J . Cell cycle-dependent induction of autophagy, mitophagy and reticulophagy. Cell Cycle. 2007; 6(18):2263-7. DOI: 10.4161/cc.6.18.4681. View

20.

Mahadevan D, Plummer R, Squires M, Rensvold D, Kurtin S, Pretzinger C . A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Ann Oncol. 2011; 22(9):2137-2143. DOI: 10.1093/annonc/mdq734. View